

# Specialty Guideline Management

## Oxervate

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Oxervate	cenegermin-bkbj

### Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-approved Indications<sup>1</sup>

Oxervate is indicated for the treatment of neurotrophic keratitis.

All other indications are considered experimental/investigational and not medically necessary.

### Prescriber Specialties

This medication must be prescribed by or in consultation with an ophthalmologist or optometrist.

### Coverage Criteria

#### Neurotrophic Keratitis<sup>1-3</sup>

Reference number(s)
2869-A

Authorization of 16 weeks (8 weeks total therapy per eye) may be granted for treatment of stage 2 and stage 3 neurotrophic keratitis when all of the following criteria are met:

- The member must experience persistent epithelial defects (PED) or corneal ulceration of at least 2 weeks duration refractory to one or more conventional non-surgical treatments (e.g., preservative free artificial tears).
- There is evidence of decreased corneal sensitivity (e.g., cotton swab method, Cochet-Bonnet contact aesthesiometer, CRCERT-Belmonte non-contact aesthesiometer) within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant.
- The member has not received a previous 8-week course of Oxervate in the affected eye.

## References

1. Oxervate [package insert]. San Mateo, CA: Dompe U.S. Inc.; February 2025.
2. Bonini S, Lambiase A, Rama P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. *Ophthalmol.* 2018;125(9):1332-1343. doi: 10.1016/j.optha.2018.02.022
3. Cunha AN, Bunya VY, Woodward MA, et al. Neurotrophic keratitis. American Academy of Ophthalmology EyeWiki. Updated January 20, 2025. Accessed October 9, 2025. [https://eyewiki.aao.org/Neurotrophic\\_Keratitis](https://eyewiki.aao.org/Neurotrophic_Keratitis).